Randomized trial highlights improved disease control in B-cell malignancies and acute myeloid leukemia, suggesting advancements in CAR-T therapy.
Dual-target chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising strategy to address the key limitations of single-target CAR-T approaches, including antigen heterogeneity and antigen-negative escape. Recent studies have reported rapid progress in the engineering of dual-target CAR-T, incorporating diverse receptor architectures, logic-gated designs, and novel manufacturing platforms. Preclinical data demonstrate improved disease control across B-cell malignancies, acute myeloid leukemia, and autoimmune disease models. Here, we summarize the latest advancements in the preclinical investigations and clinical trials of dual-target CAR-T cell therapy presented at the 2025 ASH annual meeting.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: